Treatment of arterial hypertension in patients with chronic kidney disease from the perspective of the 2023 European recommendations

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hypertension is a common disease in the adult population with an increasing tendency, it leads to damage to target organs, including the kidneys, with the development of chronic kidney disease, and increases the risk of cardiovascular complications and mortality. The paper provides an overview of the European guidelines for the treatment of arterial hypertension, updated in 2023, approved by the European Kidney Association and the International Society of Hypertension, in the context of chronic kidney disease — in comparison with the previous European guidelines (2018) and the current National clinical guidelines (2021). The updated recommendations retain the main provisions of the strategy for the treatment of arterial hypertension with chronic kidney disease of the 2018 European recommendations. Updates have been made to the classification of the main and additional groups of drugs for the treatment of arterial hypertension. For the first time, a new group of “special drugs for the treatment of concomitant pathology” has been added, including three classes of drugs: (1) neprilysin receptor antagonists, (2) sodium-glucose transporter-2 inhibitors, (3) non-steroidal mineralocorticoid receptor antagonists. A step-by-step algorithm for choosing antihypertensive drugs for arterial hypertension depending on the stage of chronic kidney disease has been updated. Recommendations for the treatment of resistant arterial hypertension were covered in detail. Some new recommendations were included for blood pressure targets based on albuminuria levels and other factors. A slightly modified scale for assessing cardiovascular risk in patients with arterial hypertension was presented and the role of chronic kidney disease stages III–V as an independent factor of high or very high cardiovascular risk was confirmed.

About the authors

Olga N. Sigitova

Kazan State Medical University

Author for correspondence.
Email: osigit@rambler.ru
ORCID iD: 0000-0001-8983-245X
SPIN-code: 3424-7909
Scopus Author ID: 6507583696
ResearcherId: AAV-1365-2021

MD, Dr. Sci. (Med.), Prof., Depart. of Polyclinic Therapy and General Medical Practice

Russian Federation, Kazan

References

  1. Boytsov SA, Balanova YuA, Shalnova SA, Deev AD, Artamonova GV, Gatagonova TM, Duplyakov DV, Efanov AYu, Zhernakova YuV, Konradi AO, Libis RA, Minakov AV, Nedogoda SV, Oshchepkova EV, Romanchuk SA, Rotar OP, Trubacheva IA, Chazova IE, Shlyakhto EV, Muromtseva GA, Evstifeeva SE, Kapustina AV, Konstantinov VV, Oganov RG, Mamedov MN, Baranova EI, Nazarova OA, Shutemova OA, Furmenko GI, Babenko NI, Azarin OG, Bondartsov LV, Khvostikova AE, Ledyaeva AA, Chumachek EV, Isaeva EN, Basyrova IR, Kondratenko VYu, Lopina EA, Safonova DV, Skripchenko AE, Indukaeva EV, Cherkass NV, Maksimov SA, Danilchenko YaV, Mulerova TA, Shalaev SV, Medvedeva IV, Shava VG, Storozhok MA, Tolparov GV, Astakhova ZT, Toguzova ZA, Kaveshnikov VS, Karpov RS, Serebryakova VN. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4–14. (In Russ.) doi: 10.15829/1728-8800-2014-4-4-14
  2. Kobalava ZhD, Villevalde SV, Borovkova NYu, Shutov AM, Nichik TE, Safuanova GS. Prevalence of markers of chronic kidney disease in patients with arterial hypertension: Results of epidemiological study CHRONOGRAF. Kardiologiia. 2017;57(10):39–44. (In Russ.) doi: 10.18087/cardio.2017.10.10041
  3. Kulakov VV, Villevalde SV, Kobalava ZD. Prevalence of renal dysfunction in patients with arterial hypertension in real clinical practice. Eurasian Heart Journal. 2016; (3):150–151. (In Russ.) EDN: XBDMFF
  4. Sigitova ON, Bogdanova AR, Saubanova EI. Risk factors, prevalence and rates of chronic kidney disease progression in outpatient patients with arterial hypertension. Terapiya. 2023;9(3):7–14. (In Russ.) doi: 10.18565/therapy.2023.3.7-14
  5. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei Е, Algharably ЕAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, de Pinho RM, Delles C, Dominiczak AF, Maorobantu M, Doumas M, Fernández-Alfonso MS, Halimi J-M, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, de Borne PhV, Wanner C, Weber T, Williams B, Zhang Z-Yu, Sverre E, Kjeldsen SE. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071. doi: 10.1097/HJH.0000000000003480
  6. Chazova IE, Chikhladze NM, Blinova NV, Belaya ZhE, Danilov NM, Elfimova EM, Litvin AYu, Rozhinskaya LYa, Sviridenko NYu, Shvetsov MYu, Azizov VA, Grigorenko EA, Mitkovskaya NP, Mustafaev II, Polupanov AG, Sarybaev ASh, Hamidullaeva GA. Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022). Eurasian Heart Journal. 2023;(1):6–65. (In Russ.) doi: 10.38109/2225-1685-2023-1-6-65
  7. Russian Medical Society for Arterial Hypertension (RMAS)/All-Russian Scientific Society of Cardiologists (VNOK). Diagnosis and treatment of arterial hypertension. Russian recommendations (fourth revision). Sistemnye gipertenzii. 2010;(3):5–26. (In Russ.) doi: 10.26442/SG28874
  8. Balanova YuA, Drapkina OM, Kutsenko VA, Imaeva AE, Kontsevaya MV, Maksimov SA, Muromtseva GA, Kotova MB, Karamnova NS, Evstifeeva SE, Kapustina AV, Litinskaya OA, Pokrovskaya MS, Filichkina EM, Ivlev OE, Gomanova LI, Doludin YuV, Efimova IA, Borisova AL, Nazarov BM, Yarovaya EB, Repkina TV, Gonoshilova TO, Kudryavtsev AV, Belova NM, Shagrov AL, Samotrueva MA, Yasenyavskaya AL, Chernysheva EN, Glukhovskaya SV, Levina IA, Shirshova EA, Dorzhieva EB, Urbanova EZ, Borovkova NYu, Kurashin VK, Tokareva AS, Ragino YuI, Simonova GI, Khudyakova AD, Nikulin VN, Aslyamov OR, Khokhlova GV, Solovyova VA, Rodionov AA, Kryachkova OV, Shamurova YuYu, Tantsyreva IV, Baryshnikova IN, Ataev MG, Radjabov MO, Isakhanova MM, Umetov MA, Elgarova LV, Khakuasheva IA, Yamashkina EI, Esina MV, Kunyaeva TA , Nikitina AM, Savvina NV, Spiridonova YuE, Naumova EA, Keskinov AA, Kashtanova DA, Yudin VS, Yudin SM, Shalnova SA. Arterial hypertension in the Russian population during the COVID-19 pandemic: Gender differences in prevalence, treatment and its effectiveness. Data from the ESSERF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.) doi: 10.15829/1728-8800-2023-3785
  9. Kobalava ZD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, Barbarash OL, Boitsov SA, Vavilova TV, Villevalde SV, Galyavich AS, Glezer MG, Grineva EN, Grinstein YuI, Drapkina OM, Zhernakova YuV, Zvartau NE, Kislyak OA, Koziolova NA, Kosmacheva ED, Kotovskaya YuV, Libis RA, Lopatin YuM, Nebiridze DV, Nedoshivin AO, Ostroumova OD, Oschepkova EV, Ratova LG, Skibitsky VV, Tkacheva ON, Chazova IE, Chesnikova AI, Chumakova GA, Shalnova SA, Shestakova MV, Yakushin SS, Yanishevsky SN. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi: 10.15829/1560-4071-2020-3-3786
  10. Muromtseva GA, Kontsevaya AV, Konstantinov VV, Artamonova GV, Gatagonova TM, Duplyakov DV, Efanov AYu, Zhernakova YuV, Ilyin VAA, Konradi AO, Libis RA, Minakov EV, Nedogoda SV, Oshchepkova EV, Romanchuk SV, Rotar OP, Trubacheva IA, Deev AD, Shalnova SV, Chazova IE, Shlyakhto EV, Boytsov SA, Balanova YuA, Gomyranova NV, Evstifeeva SE, Kapustina AV, Litinskaya OA, Mamedov MN, Metelskaya VA, Oganov RG, Suvorova EI, Khudyakov MB, Baranova EI, Kasimov RAA, Shabunova AA, Ledyaeva AA, Chumachek EV, Azarin OG, Babenko NI, Bondartsov LV, Furmenko GI, Khvostikova AE , Belova OA, Nazarova OA, Shutemova EA, Barbarash OL, Danilchenko YV, Indukaeva EV, Maksimov SA, Mulerova TA, Skripchenko AE, Cherkass NV, Basyrova IR, Isaeva EN, Kondratenko VYu, Lopina EA, Safonova DV, Gudkova SA, Cherepanova NAA, Kaveshnikov VS, Karpov RS, Serebryakova VN, Medvedeva IV, Storozhok MA, Shava VP, Shalaev SV, Gutnova SK, Tolparov GV. The prevalence of non-infectious diseases risk factors in Russian population in 2012–2013 years. The results of ESSE-RF-study. Cardiovascular Therapy and Prevention. 2014;13(6):4–11. (In Russ.) doi: 10.15829/1728-8800-2014-6-4-11
  11. Smink PA, Lambers Heerspink HJ, Gansevoort RT, Jong PE, Hillege HL, Bakker SJL, Zeeuw D. Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: The PREVEND (Prevention of Renal and Vascular Endstage Disease) study. Am J Kidney Dis. 2012;60(5):804–811. doi: 10.1053/j.ajkd.2012.06.017
  12. Chronic kidney disease. Clinical recommendations of the Russian Ministry of Health. 2021. Available from: https://rusnephrology.org/wp-content/uploads/2021/10/kr469.pdf Accessed: Jan 10, 2023. (In Russ.)
  13. Kalaitzidis RG, Elisaf MS. Treatment of hypertension in chronic kidney disease. Curr Hypertens Rep. 2018;20(8):64. doi: 10.1007/s11906-018-0864-0
  14. Zueva TV, Zhdanova TV. Arterial hypertension in chronic kidney disease: Current state of the problem. Lechaschi Vrach. 2020;(9):11–14. (In Russ.) doi: 10.26295/OS.2020.19.20.002
  15. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol. 2002;13(5):1338–1349. doi: 10.1097/01.asn.0000013291.78621.26
  16. McCullough PA, Li S, Jurkovitz CT, Lesley A, Stevens LA, Wang CH, Collins AJ, Chen S-C, Norris KC, McFarlane SI, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti JV, Whaley-Connel AT. CKD and cardiovascular disease in screened high-risk volunteer and general populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008;51(4 Suppl 2):S38–S45. doi: 10.1053/j.ajkd.2007.12.017
  17. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais H. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041. doi: 10.1097/HJH.0000000000001940
  18. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei CH, Ohashi Y, Saruta T. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: A randomized controlled trial. J Hypertens. 2011;29:1649–1659. doi: 10.1097/HJH.0b013e328348345d
  19. MacDonald TM, Williams B, Webb DJ, Steve Morant S, Caulfield M, Cruickshank JK, Ian Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J, McInnes G, Morris J. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: A double-blind randomized controlled trial. J Am Heart Assoc. 2017;6:e006986. doi: 10.1161/JAHA.117.006986
  20. Remuzzi G, Chiurchiu C, Ruggenenti P. Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN). Kidney Int Suppl. 2004;92:S90–S96. doi: 10.1111/j.1523-1755.2004.09221.x
  21. Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Na Z, Liu L, Lv J, Zhang H, Wang H. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728–4110. doi: 10.1053/j.ajkd.2015.10.011
  22. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat PH, Torp-Pedersen CH. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J. 2004;25(16):1454–1470. doi: 10.1016/j.ehj.2004.06.003
  23. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863. doi: 10.1016/S0140-6736(96)11445-8
  24. Smirnov AV, Shilov EM, Dobronravov VA, Kayukov IG, Bobkova IN, Shvetsov MYu, Tsygin AN, Shutov AM. National Guidelines. Chronic kidney disease: Basic principles of screening, diagnosis, pre- vention and treatment approaches. Nephrology (Saint-Petersburg). 2012;16(1):89–115. (In Russ.) doi: 10.24884/1561-6274-2012-16-1-89-115
  25. Pongpanich P, Pitakpaiboonkul P, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P. The benefits of angiotensin-converting enzyme inhib-itors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: A meta-analysis. Int Urol Nephrol. 2018;50(12):2261–2278. doi: 10.1007/s11255-018-1991-x
  26. Pliasheshnikov MA, Titova ZA, Volkova YuV, Zhgut OG. Pharmacotherapy of arterial hypertension in patients with chronic kidney disease in real clinical practice. Klinicheskaya farmakologiya i terapiya. 2020;29(3):80–84. (In Russ.) doi: 10.32756/0869-5490-2020-3-80-84
  27. Romanova IS, Kozhanova IS, Chack TA. Features of the use of antihypertensive drugs in patients with chronic kidney disease. Medical news. 2022;(6):44–49. (In Russ.) EDN: BRZSGB
  28. Moiseev VS, Mukhin NA, Kobalava ZhD, Bobkova IN, Villevalde SV, Efremovtseva MA, Kozlovskaya LV, Shvetsov MYu, Shestakova MV. Committee of experts: Arutyunov GP, Boytsov SA, Galyavich AS, Grinshtein YuI, Drapkina OM, Ermolenko VM, Karpov YuA, Kotovskaya YuV, Kukharchuk VV, Martynov AI, Moiseev SV, Morozova TE, Oganov RG, Podzolkov VI, Rozhinskaya LYa, Tereshchenko SN, Fomin VV, Khirmanov VN, Chazova IE, Shamkhalova MSh, Shilov EM, Shlyakhto EV, Shutov AM. Cardiovascular risk and chronic kidney disease: cardio and nephroprotection strategies. National recommendations. Clinical Nephrology. 2014;(2):4–29. (In Russ.) EDN: SGPHXP
  29. Murkamilov IT, Sabirov IS, Fomin VV, Yusupov FA. Beta blockers and renoprotection: The potential of carvedilol. Rational Pharmacotherapy in Cardiology. 2017;13(3):422–426. (In Russ.) doi: 10.20996/1819-6446-2017-13-3-422-426
  30. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2
  31. Syrov AV, Minushkina LO. Choosing the optimal thiazide-like diuretic in patients with arterial hypertension. Teraipiya. 2021;(1):172–180. (In Russ.) doi: 10.18565/therapy.2021.1.172-180
  32. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CVS, Cohen DL, Cadet J-C, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community: A statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14–26. doi: 10.1111/jch.12237
  33. Chazova I, Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study. Int J Hypertens. 2013:2013:541689. doi: 10.1155/2013/541689
  34. Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: Partners in a successful MARRIAGE? Curr Med Res Opin. 2004;20(3):359–367. doi: 10.1185/030079904125002991
  35. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell'Italia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: A prospective clinical study. Hypertension. 2010;55(5):1137–1142. doi: 10.1161/HYPERTENSIONAHA.109.141531
  36. Minushkina LO, Zateyshchikov DA. Eplerenone is a selective blocker of aldosterone receptors. Farmateka. 2007;(3):10–17. (In Russ.)
  37. Podzolkov VI, Dragomiretskaya NA. Aldosterone antagonists. Modern views on the mechanism of action and effects of spironolactone. Rational Pharmacotherapy in Cardiology. 2017;13(2):263–269. (In Russ.) doi: 10.20996/1819-6446-2017-13-2-263-269
  38. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831–1838. doi: 10.1161/01.CIR.0000091405.00772.6E
  39. Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell’Italia LJ, Cofield SS, Oparil S, Calhoun DA. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012;26(8):502–506. doi: 10.1038/jhh.2011.60
  40. Soltero Y, Guevara J, Silva H, Velasco M. A multicenter study of Doxazosin in the treatment of severe essential hypertension. Am Heart J. 1988;116(6):1767–771. doi: 10.1016/0002-8703(88)90227-x
  41. Hundemer GL, Knoll GA, Petrcich W, Hiremath S, Ruzicka M, Burns KD, Edwards C, Bugeja A, Rhodes E, Sood MM. kidney, cardiac, and safety outcomes associated with α-blockers in patients with CKD: A population-based cohort study. J Kidney Dis. 2021;77(2):178–189. doi: 10.1053/j.ajkd.2020.07.018
  42. Nebieridze DV, Gapon LI, Rotar OP, Alieva AS, Korostovtseva LS, Zvartau NE, Sviryaev YuV, Avdonina NG, Emelyanov IV, Medvedeva EA, Duplyakov DV, Barsukov AV, Karelkina EV, Moiseeva OM, Libis RA, Khirmanov VN. European recommendations for the diagnosis, treatment and prevention of arterial hypertension in 2018: Comments of the specialists of the Russian Heart Society. Arterialnaya Gipertenziya. 2018;24(6):602–622. (In Russ.) doi: 10.18705/1607–419X-2018–24–6-602-622
  43. Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: Novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001;12(3):602–605. doi: 10.1681/ASN.V123602
  44. Amman K, Rump LC, Simonavicience A, Oberhauser V, Wessels S, Orth SR, Gross M-L, Koch A, Bielenberg GW, Kats JP, Ehmke H, Mall G, Ritz E. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. 2000;1:1469–1478. doi: 10.1681/ASN.V1181469
  45. Ametov AS, Demidova TYu, Smagina LV. The cardio- and nephroprotective effects of the imidazoline receptor agonist moxonidine in the treatment of hypertension in patients with type 2 diabetes. Diabetes Mellitus. 2004;7(4):8–13. (In Russ.) EDN: ROYJQJ
  46. Katzung BG, editor. Basic & Clinical Pharmacology. 14th Edition. New York City: McGraw-Hill Education; 2018. 1264 р.
  47. Dyadyk AI, Taradin GG, Suliman YuV, Zborovskyy SR, Merkuriev VI. Diuretics in chronic kidney disease. Russian Archives of Internal Medicine. 2020;10(1):10–20. (In Russ.) doi: 10.20514/2226-6704-2020-10-1-10-20
  48. Zadionchenko VS, Schikota AM, Yalymov AA, Shehyan GG, Timofeeva NY, Oganezova LG, Terpigorev SA, Kabanova TG, Nikishenkov AM. Algorithm for choosing a drug for the treatment of arterial hypertension RMJ. 2017;(4):296–301. (In Russ.) EDN: ZWTOGD
  49. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang Sh, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. A meta-analysis. JAMA Cardiol. 2021;6(2):148–158. doi: 10.1001/jamacardio.2020.4511
  50. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon ChP, Capuano G, Chu P-L, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744
  51. Wheeler DC, Stefansson BV, Jongs N, Chertow GCh, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD, Langkilde AM, Heerspink HJL. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22–31. doi: 10.1016/S2213-8587(20)30369-7
  52. Heerspink HJL, Stefansson BY, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde A-M, Wheeler DC. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMOA2024816
  53. Shilov EM, Sigitova ON. Chronic kidney disease in the practice of primary care physicians. Terapiya. 2023;9(3):106–112. (In Russ.) doi: 10.18565/therapy.2023.3.106–112
  54. Shestakova MV, Dobronravov VA, Ametov AS, Antsiferov MB, Batyushin MM, Bobkova IN, Galstyan GR, Demidova TYu, Klimontov VV, Mkrtumyan AM, Petunina NA, Prokopenko EI, Chebotareva NV, Shamkhalova MSh. Prospects for the use of finerenone in Russian population of patients with chronic kidney disease and type 2 diabetes mellitus. Resolution of the interdisciplinary Council of Experts. Diabetes Mellitus. 2023;26(5):492–499. (In Russ.) doi: 10.14341/DM13020
  55. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 2016;387:957–967. doi: 10.1016/S0140-6736(15)01225-8
  56. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie ChL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: A randomized clinical trial. JAMA. 2016;315:2673–2682. doi: 10.1001/jama.2016.7050
  57. Hao G, Wang Z, Guo R, Chen Z, Wang X, Zhang L, Li W. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled studies. BMC Cardiovasc Disord. 2014;14(1):148. doi: 10.1186/1471-2261-14-148
  58. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels — updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613–622. doi: 10.1097/HJH.0000000000000881
  59. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1–S87. doi: 10.1016/j.kint.2020.11.003
  60. SPRINT Research Group, Wright JT Jr, Williamson JD, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116. doi: 10.1056/NEJMoa1511939
  61. National recommendations “Cardiovascular risk and chronic kidney disease: Strategies for cardio-nephroprotection”. Russian Journal of Cardiology. 2014;8(112):7–37. (In Russ.) EDN: SMGWFL
  62. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ. British Hypertension Society"s PATHWAY studies group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet. 2015;386:2059–2068. doi: 10.1016/S0140-6736(15)00257-3
  63. Carey RM, Calhoun DA, Bakris GL. Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension. 2018; 72(5):e53–e90. doi: 10.1161/HYP.0000000000000084
  64. Wood S. EMA: Don't combine ARBs, ACE inhibitors, and direct renin inhibitors. 2014. Available from: http://www.medscape.com Accessed: Jan 15, 2024.
  65. Fried LF, Emanuele N, Zhang JH, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P. NEPHRON-D investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–1903. doi: 10.1056/NEJMoa1303154
  66. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET investigators, telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559. doi: 10.1056/NEJMoa0801317
  67. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–917. doi: 10.1161/HYPERTENSIONAHA.110.163014
  68. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–1281. doi: 10.1016/S0140-6736(09)60566-3
  69. Mackenzie IS, Rogers A, Poulter NR, Williams В, Brown MJ, Webb DJ, Ford I, Rorie DA, Guthrie G, Grieve JWK, Pigazzani F, Rothwell PM, Young R, McConnachie A, Struthers AD, Lang CC, MacDonald T. Cardiovascular outcomes in adults with hypertension with evening vs morning dosing of usual antihypertensives in the UK (TIME study): A prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022;400:1417–1425. doi: 10.1016/S0140-6736(22)01786-X

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Supplement 1
Download (38KB)
Indexing metadata
3. Supplement 2
Download (82KB)
Indexing metadata
4. Supplement 3
Download (41KB)
Indexing metadata

© 2024 Eco-Vector




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies